ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity – AdoXLong – and Provides an Update on its BioChaperone® Platform

Adocia Logo

Advancing Mealtime Insulin Therapy:
Phase 3 Results for BC Lispro in Type 2 Diabetes

Tuesday, June 16, 2026 | 10:00 AM ET / 4:00 PM CET

Click Here to Register & Attend